Reviewing Research On CBD For COVID-19 Therapy

**IMPORTANT DISCLAIMER: This article is an educational review of early-stage scientific research only. CBD is not approved by the U.S. Food and Drug Administration (FDA) to prevent, treat, cure, or mitigate COVID-19 or any other disease. The studies discussed below are preliminary, involve laboratory or animal models, and have not been validated in large-scale human clinical trials. Nothing in this article should be construed as medical advice. Consult a qualified healthcare professional before making any decisions about COVID-19 prevention or treatment.

Introduction

The COVID-19 pandemic sparked unprecedented scientific interest in potential therapeutic compounds — including cannabidiol (CBD), the non-psychoactive cannabinoid found in hemp. As researchers explored every plausible avenue for managing the disease, a small but growing body of preclinical and early clinical research began examining CBD's potential interactions with SARS-CoV-2, the virus responsible for COVID-19.

This article fromPureCraft CBD provides an objective review of that emerging research — what has been studied, what the preliminary findings suggest, and critically, what those findings donot mean for consumers. We believe in science-based transparency: sharing what researchers have explored while being unambiguous that this research is far from sufficient to support any therapeutic claims about CBD for COVID-19.

Background: Why Researchers Looked at CBD

CBD is a phytocannabinoid that interacts with the body's endocannabinoid system (ECS) — a regulatory network involved in immune function, inflammation, pain signaling, and cell stress responses. Several pre-existing properties of CBD drew the attention of researchers investigating COVID-19:

These biological plausibility arguments provided a scientific rationale for studying CBD in the context of COVID-19 — though biological plausibility is only the first step in a long chain of evidence required before any therapeutic claim can be made.

Key Studies and Their Findings

1. Preclinical Anti-Inflammatory Research

A widely discussed 2021 study by Khodadadi et al. published inCannabis and Cannabinoid Research examined CBD's effect on cytokine profiles in a laboratory model relevant to COVID-19-associated lung injury. The researchers found that CBD treatment was associated with reduced levels of pro-inflammatory cytokines and improved oxygen saturation markers in the model.

Importantly, the authors concluded that the findings werepreliminary and that "further investigation and clinical trials are necessary before CBD can be considered as a therapeutic option" for COVID-19 complications. The study did not involve human patients and did not test CBD against SARS-CoV-2 directly.

2. CBD and Lung Injury Models

A 2020 study published inJournal of Cellular and Molecular Medicine by Salles et al. examined CBD's effects on lung inflammation in animal models. The researchers found that CBD appeared to reduce pulmonary inflammation and improve lung function metrics in the model — properties potentially relevant to COVID-19-related respiratory complications.

Again, these findings were in animal models, not human patients with COVID-19. The researchers explicitly noted the limitations of translating animal model findings to human disease.

3. CBD and SARS-CoV-2 Viral Entry

A 2022 study published inScience Advances by Nguyen et al. at the University of Chicago examined CBD's effects on SARS-CoV-2 in cell culture (in vitro). The researchers reported that CBD appeared to inhibit SARS-CoV-2 replication in the cell culture model and that a CBD metabolite (7-OH-CBD) showed similar activity.

This study generated significant media attention. However, the researchers themselves issued cautions: the findings were from cell culture experiments, not human studies; CBD doses required to achieve these effects were not established as safe or achievable in humans; and the study"does not indicate that CBD should be used to prevent or treat COVID-19 in humans."The FDA later cited concerns about this study being misrepresented to promote CBD products for COVID-19 prevention.

4. Observational Data on CBD Users

Some retrospective data analyses examined COVID-19 outcomes in patients who reported using CBD vs. those who did not. A 2022 analysis published inCannabis and Cannabinoid Research suggested some associations between CBD use and milder COVID-19 symptoms in certain patient groups. However, observational studies of this type cannot establish causation, are subject to significant confounding variables, and represent the weakest form of clinical evidence.

5. The National Institutes of Health (NIH) Interest

The NIH funded several studies exploring cannabinoids and COVID-19 pathophysiology as part of the broader pandemic research response. This funding reflects the scientific community's recognition that the mechanistic questions are worth exploring — not an endorsement of CBD as a COVID-19 treatment.

What the Research Does NOT Show

It is essential to be clear about the significant limitations of the research reviewed above:

The FDA's Position on CBD and COVID-19

The FDA has been explicit and consistent:CBD is not approved to treat, cure, mitigate, or prevent COVID-19. The agency has issued warning letters to numerous companies that marketed CBD products with COVID-19 claims — including companies that cited the same preliminary research discussed in this article.

In a public statement, the FDA noted: "There is no scientific evidence that CBD products are useful for COVID-19 treatment or prevention... consumers should be cautious of claims that CBD will treat or cure COVID-19." The full FDA guidance is available atFDA.gov.

PureCraft CBD fully supports this regulatory position. We make no claims that any of our products treat, prevent, or cure COVID-19 or any other disease. Our products are sold as dietary supplements for general wellness purposes only.

Summary of Research Landscape

Understanding the Research Pipeline

For context, this is how medical research typically progresses before a treatment can be recommended:

Current CBD and COVID-19 research has not progressed beyond early steps 1 and 2 for most findings. Steps 3 through 6 — which take years and substantial resources — have not been completed.

Why We're Discussing This At All

A reasonable question: if the evidence is this preliminary, why cover it?

The answer is that consumers deserve accurate information. When headlines declare "CBD may fight COVID-19" based on a cell culture study, many people draw conclusions the research does not support. By placing the science in context — explaining what was actually studied, what it found, and what its limitations are — we aim to help consumers make informed decisions rather than decisions based on hype.

Understanding the difference between "researchers are exploring whether X might have Y effect in a laboratory model" and "X treats Y in humans" is one of the most important health literacy skills anyone can develop.

What You Can Do for COVID-19

The most evidence-based approaches to COVID-19 prevention and management remain:

For current, evidence-based COVID-19 information, visit theCDC andFDA.

Frequently Asked Questions

Is CBD proven to treat COVID-19?

No. There are no completed human clinical trials demonstrating that CBD treats, prevents, or cures COVID-19. The research to date consists primarily of laboratory and animal studies that establish biological plausibility, not therapeutic efficacy.

Does the FDA approve CBD for COVID-19?

No. The FDA has not approved any CBD product for any COVID-19 indication. The only FDA-approved CBD medication (Epidiolex) is approved solely for rare seizure disorders.

Should I take CBD instead of getting vaccinated against COVID-19?

No. There is no scientific basis for replacing vaccination — which has robust clinical trial evidence — with CBD. Vaccination remains the most effective evidence-based tool for preventing severe COVID-19.

What did the University of Chicago CBD study actually find?

The 2022 Science Advances study found that CBD inhibited SARS-CoV-2 replication in cell cultures (a laboratory dish environment). The researchers themselves stated this does not indicate CBD should be used to prevent or treat COVID-19 in humans. Cell culture findings frequently do not translate to human outcomes.

Why does CBD have anti-inflammatory properties?

CBD interacts with multiple receptors involved in immune and inflammatory signaling, including CB2 receptors, TRPV1 receptors, and GPR55 receptors. It has also been shown to inhibit cyclooxygenase enzymes (similar to NSAIDs) and reduce pro-inflammatory cytokine expression. These mechanisms are well-established in preclinical research, but their relevance to COVID-19 treatment in humans has not been clinically validated.

Can CBD help with COVID-19 symptoms like inflammation?

While CBD has preclinical evidence for anti-inflammatory properties, no clinical trial has established that CBD products available to consumers effectively treat COVID-19-related inflammation in humans. Using any supplement for COVID-19 symptom management should be discussed with a healthcare provider.

Are researchers still studying CBD for COVID-19?

Yes. Research interest continues. Several academic institutions and research groups have ongoing investigations into cannabinoids and COVID-19 pathophysiology. This is scientifically legitimate exploratory research. If future rigorous clinical trials produce positive results, the scientific and regulatory community will evaluate and disseminate those findings appropriately.

What is cytokine storm and does CBD affect it?

Cytokine storm is a hyperinflammatory immune response in which the body produces excessive pro-inflammatory cytokines, causing widespread tissue damage. It is a significant contributor to severe COVID-19 outcomes. Preclinical studies have shown that CBD reduces cytokine production in laboratory models — but this has not been demonstrated in human COVID-19 patients in a clinical trial.

Does PureCraft CBD claim its products treat COVID-19?

No, absolutely not. PureCraft CBD makes no claims that any of our products treat, prevent, or cure COVID-19 or any other disease. Our products are sold as dietary supplements and have not been evaluated by the FDA for any medical purpose.

Where can I find accurate COVID-19 treatment information?

TheCDC andFDA provide the most current, evidence-based guidance on COVID-19 prevention and treatment. Your healthcare provider is the best resource for personal medical advice.

Conclusion

The research exploring CBD in the context of COVID-19 is scientifically interesting — but it is early, preliminary, and limited to laboratory and animal models. No human clinical trial has established that CBD treats, prevents, or mitigates COVID-19. The FDA has not approved any CBD product for any COVID-19 indication, and has explicitly warned against such claims.

PureCraft CBD believes in science, transparency, and responsible communication. We share this research review because an informed consumer is a better consumer — not to imply that our products have any role in COVID-19 treatment. We encourage everyone to rely on evidence-based healthcare guidance from the CDC, FDA, and qualified medical professionals for all COVID-19-related decisions.

For general wellness products with transparent, third-party lab results, explorePureCraft CBD's full collection. View ourpublished lab results for complete product transparency.

Sources & Citations

Related Articles